anne_whitaker

Synta appoints Sanofi president as chief executive

pharmafile | August 11, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Synta, anne whitaker 

US biopharma firm Synta Pharmaceuticals has confirmed that Anne Whitaker is joining the company as president and chief executive.

Whitaker who is to join Synta in September, has more than 20 years of experience in the pharma industry covering roles at GlaxoSmithKline but also Sanofi, which includes her recent position there as its president, North America Pharmaceuticals.

Whitaker began her career at Delta Communications and joined the Upjohn Company in 1991 as a metabolic disease specialist. Joining GSK in 1992 as a sales representative she then went on to hold various leadership positions before starting with Sanofi in 2011.

Advertisement

“It is with great pleasure that the Board welcomes Anne Whitaker as Synta’s new chief executive,” says Keith Gollust, chairman of the board of Synta. “Anne brings a wealth of experience to Synta, gained over a distinguished career in executive roles with two of the world’s top pharmaceutical companies.”

Whitaker adds: “I am excited to join the very talented and dedicated team at Synta at this important time in the company’s evolution.”

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content